1
|
Ma Q, Luo R, Zhang H, Dai M, Bai L, Fei Q, Lei F, He N. Design, Characterization, and Application of a pH-Triggered In Situ Gel for Ocular Delivery of Vinpocetine. AAPS PharmSciTech 2020; 21:253. [PMID: 32888086 DOI: 10.1208/s12249-020-01791-0] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/16/2020] [Accepted: 08/18/2020] [Indexed: 01/14/2023] Open
Abstract
We developed a pH-triggered in situ gel (ISG) for ocular delivery of vinpocetine to achieve systemic absorption and a brain-targeting effect in rats. Carbopol acted as a gelling agent combined with hydroxypropyl methylcellulose (HPMC) as a viscosity-enhancing agent. The concentration of Carbopol (0.2%, w/v) and HPMC (1.5%, w/v) was optimized for the ISG system. The optimized formulation was evaluated for studies on release in vitro, rheology, differential scanning calorimetry, ocular irritation, residence time, and in vivo pharmacokinetics. The vinpocetine ISG stayed longer in rabbit eyes than vinpocetine ointment. In vivo pharmacokinetics showed that compared with vinpocetine ointment, vinpocetine ISG attained a peak plasma concentration and area under the curve that was 1-2 folds greater in rat plasma. The Drug Targeting Index (DTI) was 1.06 and 1.26 for vinpocetine ointment and vinpocetine ISG, respectively, after ocular administration, showing that vinpocetine ISG had better distribution in rat brain. These results revealed that a pH-triggered ISG system via ocular administration could be an alternative approach compared with traditional ophthalmic formulations.
Collapse
|
2
|
Dave VS, Gupta D, Yu M, Nguyen P, Varghese Gupta S. Current and evolving approaches for improving the oral permeability of BCS Class III or analogous molecules. Drug Dev Ind Pharm 2016; 43:177-189. [PMID: 27998192 DOI: 10.1080/03639045.2016.1269122] [Citation(s) in RCA: 25] [Impact Index Per Article: 3.1] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022]
Abstract
The Biopharmaceutics Classification System (BCS) classifies pharmaceutical compounds based on their aqueous solubility and intestinal permeability. The BCS Class III compounds are hydrophilic molecules (high aqueous solubility) with low permeability across the biological membranes. While these compounds are pharmacologically effective, poor absorption due to low permeability becomes the rate-limiting step in achieving adequate bioavailability. Several approaches have been explored and utilized for improving the permeability profiles of these compounds. The approaches include traditional methods such as prodrugs, permeation enhancers, ion-pairing, etc., as well as relatively modern approaches such as nanoencapsulation and nanosizing. The most recent approaches include a combination/hybridization of one or more traditional approaches to improve drug permeability. While some of these approaches have been extremely successful, i.e. drug products utilizing the approach have progressed through the USFDA approval for marketing; others require further investigation to be applicable. This article discusses the commonly studied approaches for improving the permeability of BCS Class III compounds.
Collapse
Affiliation(s)
- Vivek S Dave
- a Wegmans School of Pharmacy , St. John Fisher College , Rochester , NY , USA
| | - Deepak Gupta
- b Lake Eerie College of Osteopathic Medicine , School of Pharmacy, Pharmaceutical Sciences , Bradenton , FL , USA
| | - Monica Yu
- b Lake Eerie College of Osteopathic Medicine , School of Pharmacy, Pharmaceutical Sciences , Bradenton , FL , USA
| | - Phuong Nguyen
- b Lake Eerie College of Osteopathic Medicine , School of Pharmacy, Pharmaceutical Sciences , Bradenton , FL , USA
| | - Sheeba Varghese Gupta
- c Department of Pharmaceutical Sciences , USF College of Pharmacy , Tampa , FL , USA
| |
Collapse
|
3
|
Sattar M, Sayed OM, Lane ME. Oral transmucosal drug delivery--current status and future prospects. Int J Pharm 2014; 471:498-506. [PMID: 24879936 DOI: 10.1016/j.ijpharm.2014.05.043] [Citation(s) in RCA: 77] [Impact Index Per Article: 7.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/17/2014] [Revised: 05/14/2014] [Accepted: 05/26/2014] [Indexed: 10/25/2022]
Abstract
Oral transmucosal drug delivery (OTDD) dosage forms have been available since the 1980s. In contrast to the number of actives currently delivered locally to the oral cavity, the number delivered as buccal or sublingual formulations remains relatively low. This is surprising in view of the advantages associated with OTDD, compared with conventional oral drug delivery. This review examines a number of aspects related to OTDD including the anatomy of the oral cavity, models currently used to study OTDD, as well as commercially available formulations and emerging technologies. The limitations of current methodologies to study OTDD are considered as well as recent publications and new approaches which have advanced our understanding of this route of drug delivery.
Collapse
Affiliation(s)
- Mohammed Sattar
- Department of Pharmaceutics, UCL School of Pharmacy, 29-39 Brunswick Square, London WC1 N 1AX, United Kingdom; Department of Pharmaceutics, College of Pharmacy, University of Basrah, Basrah, Iraq
| | - Ossama M Sayed
- Department of Pharmaceutics, UCL School of Pharmacy, 29-39 Brunswick Square, London WC1 N 1AX, United Kingdom; Pharmaceutics Department, Faculty of Pharmacy, Beni Suef University, P.O. Box 62514, Egypt
| | - Majella E Lane
- Department of Pharmaceutics, UCL School of Pharmacy, 29-39 Brunswick Square, London WC1 N 1AX, United Kingdom.
| |
Collapse
|
4
|
Hauptstein S, Bonengel S, Griessinger J, Bernkop-Schnürch A. Synthesis and characterization of pH tolerant and mucoadhesive (thiol-polyethylene glycol) chitosan graft polymer for drug delivery. J Pharm Sci 2013; 103:594-601. [PMID: 24382680 DOI: 10.1002/jps.23832] [Citation(s) in RCA: 28] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/01/2013] [Revised: 12/06/2013] [Accepted: 12/06/2013] [Indexed: 11/11/2022]
Abstract
The objective of this study was to generate a water-soluble thiolated chitosan to enable the permeation-enhancing effect of chitosan at pH of at least 5.5 without losing the advantages of improved mucoadhesive properties. Therefore, the thiol-bearing polyoxyethylene ligand {O-(3-carboxylpropyl)-O'-[2-[3-mercaptopropionylamino)ethyl]-polyethyleneglycol} was conjugated via amide bond formation to the amino group of chitosan. Resulting novel chitosan derivative (Chito-PEG-SH) exhibited 250 μmol free thiol groups per gram polymer. By the attachment of the thiol-bearing PEG ligand, an improvement of permeation-enhancing effect on rat intestine (2.7-fold improvement) as well as on a Caco-2 monolayer model (1.9-fold improvement) could be found. Cytotoxicity studies on Caco-2 cells revealed no change in biocompatibility. Mucoadhesion was improved 3.1-fold by the formation of disulfide bonds with mucus glycoproteins. The mucoadhesive effect of Chito-PEG-SH turned out to be similar to thiolated chitosan and more pronounced than mucoadhesive properties of unmodified chitosan. The graft polymer is soluble in water and aqueous solutions over a broad pH range. In aqueous media, the novel polymer does not precipitate at pH of 8.6 or less. According to these results, Chito-PEG-SH might show potential as auxiliary agent in oral drug delivery where its solubility even up to pH 8 is likely beneficial.
Collapse
Affiliation(s)
- Sabine Hauptstein
- Center for Chemistry and Biomedicine, Center for Molecular Biosciences, Department of Pharmaceutical Technology, Institute of Pharmacy, University of Innsbruck, Innsbruck, 6020, Austria
| | | | | | | |
Collapse
|
5
|
Oromucosal delivery of venlafaxine by linseed mucilage based gel: in vitro and in vivo evaluation in rabbits. Arch Pharm Res 2013; 36:846-53. [DOI: 10.1007/s12272-013-0097-3] [Citation(s) in RCA: 16] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/28/2011] [Accepted: 08/11/2011] [Indexed: 11/25/2022]
|
6
|
Sohi H, Ahuja A, Ahmad FJ, Khar RK. Critical evaluation of permeation enhancers for oral mucosal drug delivery. Drug Dev Ind Pharm 2010. [DOI: 10.3109/03639040903117348] [Citation(s) in RCA: 78] [Impact Index Per Article: 5.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022]
|
7
|
Atlasz T, Szabadfi K, Kiss P, Tamas A, Toth G, Reglodi D, Gabriel R. Evaluation of the protective effects of PACAP with cell-specific markers in ischemia-induced retinal degeneration. Brain Res Bull 2009; 81:497-504. [PMID: 19751807 DOI: 10.1016/j.brainresbull.2009.09.004] [Citation(s) in RCA: 51] [Impact Index Per Article: 3.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/06/2009] [Accepted: 09/08/2009] [Indexed: 01/26/2023]
Abstract
Pituitary adenylate cyclase activating polypeptide (PACAP) is a neurotrophic and neuroprotective peptide that has been shown to exert protective effects in different neuronal injuries, such as traumatic brain injury, models of neurodegenerative diseases and cerebral ischemia. We have provided evidence that PACAP is neuroprotective in several models of retinal degeneration in vivo. In our previous studies we showed that PACAP treatment significantly ameliorated the damaging effects of permanent bilateral common carotid artery occlusion (BCCAO). In the present study cell-type-specific markers were used in the same models in order to further specify the protective effects of PACAP. In rats BCCAO led to severe degeneration of all retinal layers that was attenuated by PACAP (100 pmol) administered unilaterally immediately following BCCAO into the vitreous body of one eye. Retinas were processed for immunohistochemistry after 3 weeks. Immunolabeling was executed for vesicular glutamate transporter 1 (VGLUT 1), vesicular gamma-aminobutyric acid transporter (VGAT), protein kinase Calpha (PKCalpha), glial fibrillary acidic protein (GFAP) and calcium-binding proteins, such as calbindin, calretinin, parvalbumin. In BCCAO retinas, intensity of immunopositivity for all antisera was dramatically decreased, except in the case of GFAP. In PACAP-treated retinas, immunostaining was similar to that of the control animals. In summary, our study presented immunohistochemical identification of cell types sensitive to chronic retinal hypoperfusion and the protective effects of PACAP. This analysis revealed that the retinoprotective effects of PACAP are not phenotype-specific, but it rather influences general cytoprotective pathways irrespective of the neuronal subtypes in the retina subjected to chronic hypoperfusion.
Collapse
Affiliation(s)
- Tamas Atlasz
- Department of Experimental Zoology and Neurobiology, University of Pecs, Pecs, Hungary.
| | | | | | | | | | | | | |
Collapse
|
8
|
Kulkarni U, Mahalingam R, Pather S, Li X, Jasti B. Porcine Buccal Mucosa as an In Vitro Model: Relative Contribution of Epithelium and Connective Tissue as Permeability Barriers. J Pharm Sci 2009; 98:471-83. [DOI: 10.1002/jps.21436] [Citation(s) in RCA: 40] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
|
9
|
In vitro evaluation of natural and methylated cyclodextrins as buccal permeation enhancing system for omeprazole delivery. Eur J Pharm Biopharm 2009; 71:339-45. [DOI: 10.1016/j.ejpb.2008.08.016] [Citation(s) in RCA: 33] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/26/2008] [Revised: 07/25/2008] [Accepted: 08/07/2008] [Indexed: 11/23/2022]
|
10
|
Thakur RA, Michniak BB, Meidan VM. Transdermal and Buccal Delivery of Methylxanthines Through Human Tissue In Vitro. Drug Dev Ind Pharm 2008; 33:513-21. [PMID: 17520442 DOI: 10.1080/03639040600901994] [Citation(s) in RCA: 19] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022]
Abstract
We examined the in vitro permeation of central nervous stimulants - caffeine, theophylline, and theobromine across human skin with the aid of six chemical enhancers. It was found that oleic acid was the most potent enhancer for all three methylxanthines. Further optimization studies with different solvents showed that caffeine transport could be enhanced to give flux values up to 585 microg/cm2.hr-1. Theobromine and theophylline delivery rates proved insufficient. An additional study involving a buccal tissue equivalent showed that this membrane was more permeable than skin for all model actives tested and would offer an alternate way of delivery.
Collapse
Affiliation(s)
- Rashmi A Thakur
- Ernest Mario School of Pharmacy, Rutgers, The State University of New Jersey, Piscataway, NJ 08854, USA
| | | | | |
Collapse
|
11
|
Di Colo G, Zambito Y, Zaino C. Polymeric Enhancers of Mucosal Epithelia Permeability: Synthesis, Transepithelial Penetration-Enhancing Properties, Mechanism of Action, Safety Issues. J Pharm Sci 2008; 97:1652-80. [PMID: 17828745 DOI: 10.1002/jps.21043] [Citation(s) in RCA: 82] [Impact Index Per Article: 5.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/07/2022]
Abstract
Transmucosal drug administration across nasal, buccal, and ocular mucosae is noninvasive, eliminates hepatic first-pass metabolism and harsh environmental conditions, allows rapid onset, and further, mucosal surfaces are readily accessible. Generally, however, hydrophilic drugs, such as peptides and proteins, are poorly permeable across the epithelium, which results in insufficient bioavailability. Therefore, reversible modifications of epithelial barrier structure by permeation enhancers are required. Low molecular weight enhancers generally have physicochemical characteristics favoring their own absorption, whereas polymeric enhancers are not absorbed, and this minimizes the risk of systemic toxicity. The above considerations have warranted the present survey of the studies on polymeric transmucosal penetration-enhancers that have appeared in the literature during the last decade. Studies on intestinal permeation enhancers are also reviewed as they give information on the mechanism of action and safety of polymers. The synthesis and characterization of polymers, their effectiveness in enhancing the absorption of different drugs across different epithelium types, their mechanism of action and structure-efficacy relationship, and the relevant safety issues are reviewed. The active polymers are classified into: polycations (chitosan and its quaternary ammonium derivatives, poly-L-arginine (poly-L-Arg), aminated gelatin), polyanions (N-carboxymethyl chitosan, poly(acrylic acid)), and thiolated polymers (carboxymethyl cellulose-cysteine, polycarbophil (PCP)-cysteine, chitosan-thiobutylamidine, chitosan-thioglycolic acid, chitosan-glutathione conjugates).
Collapse
Affiliation(s)
- Giacomo Di Colo
- Department of Bioorganic Chemistry and Biopharmaceutics, University of Pisa, Via Bonanno 33, 56126 Pisa, Italy.
| | | | | |
Collapse
|
12
|
Kremser C, Albrecht K, Greindl M, Wolf C, Debbage P, Bernkop-Schnürch A. In vivo determination of the time and location of mucoadhesive drug delivery systems disintegration in the gastrointestinal tract. Magn Reson Imaging 2008; 26:638-43. [PMID: 18436409 DOI: 10.1016/j.mri.2008.01.004] [Citation(s) in RCA: 18] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/09/2007] [Revised: 12/19/2007] [Accepted: 01/07/2008] [Indexed: 12/17/2022]
Abstract
OBJECTIVE The objective of this study was to use magnetic resonance imaging (MRI) to detect the time when and the location at which orally delivered mucoadhesive drugs are released. MATERIALS AND METHODS Drug delivery systems comprising tablets or capsules containing a mucoadhesive polymer were designed to deliver the polymer to the intestine in dry powder form. Dry Gd-DTPA [diethylenetriaminepentaacetic acid gadolinium(III) dihydrogen salt hydrate] powder was added to the mucoadhesive polymer, resulting in a susceptibility artifact that allows tracking of the application forms before their disintegration and that gives a strong positive signal on disintegration. Experiments were performed with rats using T(1)-weighted spin-echo imaging on a standard 1.5-T MRI system. RESULTS The susceptibility artifact produced by the dry Gd-DTPA powder in tablets or capsules was clearly visible within the stomach of the rats and could be followed during movement towards the intestine. Upon disintegration, a strong positive signal was unambiguously observed. The time between ingestion and observation of a positive signal was significantly different for different application forms. Quantification of the remaining mucoadhesive polymer in the intestine 3 h after observed release showed significant differences in mucoadhesive effectiveness. CONCLUSION MRI allows detection of the exact time of release of the mucoadhesive polymer in vivo, which is a prerequisite for a reliable quantitative comparison between different application forms.
Collapse
Affiliation(s)
- Christian Kremser
- Department of Radiology, Innsbruck Medical University, A-6020 Innsbruck, Austria.
| | | | | | | | | | | |
Collapse
|
13
|
Hombach J, Hoyer H, Bernkop-Schnürch A. Thiolated chitosans: Development and in vitro evaluation of an oral tobramycin sulphate delivery system. Eur J Pharm Sci 2008; 33:1-8. [DOI: 10.1016/j.ejps.2007.09.001] [Citation(s) in RCA: 42] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/11/2007] [Revised: 08/29/2007] [Accepted: 09/04/2007] [Indexed: 11/26/2022]
|
14
|
|
15
|
Albrecht K, Greindl M, Kremser C, Wolf C, Debbage P, Bernkop-Schnürch A. Comparative in vivo mucoadhesion studies of thiomer formulations using magnetic resonance imaging and fluorescence detection. J Control Release 2006; 115:78-84. [PMID: 16901569 DOI: 10.1016/j.jconrel.2006.06.023] [Citation(s) in RCA: 35] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/26/2006] [Revised: 06/19/2006] [Accepted: 06/22/2006] [Indexed: 10/24/2022]
Abstract
The aim of this study was to compare different oral delivery systems based on the thiolated polymer polycarbophil-cysteine (PCP-Cys) and to provide evidence for the validity of the hypothesis that unhydrated polymers provide better mucoadhesion in vivo. To achieve dry polymer application, a new, experimental dosage form named Eutex (made of Eudragit L100-55 and latex) capsule has been developed. Magnetic resonance imaging was used to localize the point of release of the thiolated polymer from the application forms via the positive magnetic resonance signal from a gadolinium complex (Gd-DTPA). In vivo mucoadhesion was determined by ascertaining the residence time of the fluorescence-tagged thiomer on intestinal mucosa after 3 h. Results showed that in comparison to conventional application forms the Eutex capsules led to 1.9-fold higher mucoadhesive properties of PCP-Cys when compared to application with a conventional enteric-coated capsule, and to 1.4-fold higher mucoadhesion when compared to administration with an enteric-coated tablet of the thiomer. The findings of this study should contribute to the understanding of mucoadhesion and mucoadhesion influencing parameters in vivo and should therefore be of considerable interest for the development of future mucoadhesive oral drug delivery dosage forms.
Collapse
Affiliation(s)
- K Albrecht
- Department of Pharmaceutical Technology, Institute of Pharmacy, Leopold-Franzens-University Innsbruck, Josef-Möller-Haus, Innrain 52, 6020 Innsbruck, Austria
| | | | | | | | | | | |
Collapse
|
16
|
Langoth N, Kahlbacher H, Schöffmann G, Schmerold I, Schuh M, Franz S, Kurka P, Bernkop-Schnürch A. Thiolated Chitosans: Design and In Vivo Evaluation of a Mucoadhesive Buccal Peptide Drug Delivery System. Pharm Res 2006; 23:573-9. [PMID: 16411147 DOI: 10.1007/s11095-005-9533-5] [Citation(s) in RCA: 54] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/10/2005] [Accepted: 11/15/2005] [Indexed: 10/25/2022]
Abstract
PURPOSE Intravenous application of pituitary adenylate cyclase-activating polypeptide (PACAP) has been identified as a promising strategy for the treatment of type 2 diabetes. To generate a more applicable formulation, it was the aim of this study to develop a sustained buccal delivery system for this promising therapeutic peptide. METHODS 2-Iminothiolane was covalently bound to chitosan to improve the mucoadhesive and permeation-enhancing properties of chitosan used as drug carrier matrix. The resulting chitosan-4-thiobutylamidine conjugate was homogenized with the enzyme inhibitor and permeation mediator glutathione (gamma-Glu-Cys-Gly), Brij 35, and PACAP (formulation A). The mixture was lyophilized and compressed into flat-faced discs (18 mm in diameter). One formulation was additionally coated on one side with palm wax (formulation B). Tablets consisting of unmodified chitosan and PACAP (formulation C) or of unmodified chitosan, Brij 35, and PACAP (formulation D) served as controls. Bioavailability studies were performed in pigs by buccal administration of these test formulations. Blood samples were analyzed via an ELISA method. RESULTS Formulations A and B led to an absolute bioavailability of 1%, whereas PACAP did not reach the systemic circulation when administered via formulations C and D. Moreover, in the case of formulations A and B, a continuously raised plasma level of the peptide drug being in the therapeutic range could be maintained over the whole period of application (6 h). Formulations A and B were removed by moderate force from the buccal mucosa after 6 h, whereas formulations C and D detached from the mucosa 4 h after application. CONCLUSION The study reveals this novel mucoadhesive delivery system to be a promising approach for buccal delivery of PACAP.
Collapse
Affiliation(s)
- Nina Langoth
- Thiomatrix GmbH, Mitterweg 24, A-6020, Innsbruck, Austria.
| | | | | | | | | | | | | | | |
Collapse
|
17
|
Langoth N, Bernkop-Schnürch A, Kurka P. In vitro evaluation of various buccal permeation enhancing systems for PACAP (pituitary adenylate cyclase-activating polypeptide). Pharm Res 2005; 22:2045-50. [PMID: 16132338 DOI: 10.1007/s11095-005-7894-4] [Citation(s) in RCA: 27] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/16/2005] [Accepted: 08/09/2005] [Indexed: 10/25/2022]
Abstract
PURPOSE Buccal administration of pituitary adenylate cyclase-activating polypeptide (PACAP) could represent a new possibility for the treatment of type 2 diabetes. In this study the effect of various buccal permeation enhancers on PACAP and FD-4 was evaluated. METHODS The permeation-enhancing properties of the well-established permeation enhancers sodium deoxycholate (Na DOC) and cetrimide on the permeation of PACAP were investigated on freshly excised porcine buccal mucosa in Ussing chambers. Furthermore, the effect of chitosan and that of chitosan-4-thiobutylamidine conjugate (chitosan-TBA) optionally in combination with reduced glutathione (GSH) on the permeation of PACAP across the buccal mucosa was studied. RESULTS The apparent permeability coefficient (P(app)) of PACAP in buffer only was 5.7 +/- 3.1x10(-8) cm/s. In the presence of 5% (m/v) Na DOC, the enhancement of the permeation was 18.6-fold, whereas due to the addition of 5% (m/v) cetrimide an enhancement ratio of 46.5 was obtained. In the presence of the chitosan-TBA conjugate (1%), a 38.9-fold increased permeation was achieved, whereas unmodified chitosan (1%) did not show any effect. The combination of chitosan-TBA conjugate (1%) with GSH (2%) led to an increase in P(app) up to 441.7 +/- 89.9x10(-8) cm/s, which represents a 77.5-fold improvement. The P(app) of GSH per se was only 1.0 +/- 0.2x10(-9) cm/s, showing that GSH remains concentrated on the surface of the buccal mucosa. Results were confirmed by additional permeation studies performed with FD-4 used as hydrophilic macromolecular test compound. CONCLUSIONS Based on their permeation-enhancing properties, chitosan-TBA conjugates represent a promising tool for the buccal administration of peptide drugs, e.g., PACAP.
Collapse
Affiliation(s)
- Nina Langoth
- ThioMatrix GmbH, Mitterweg 24, A-6020, Innsbruck, Austria.
| | | | | |
Collapse
|